- Home
- CTNM vs LYEL Comparison
CTNM vs LYEL Comparison
Compare CTNM & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTNM
- LYEL
- Stock Information
- Founded
- CTNM 2009
- LYEL 2018
- Country
- CTNM United States
- LYEL United States
- Employees
- CTNM N/A
- LYEL N/A
- Industry
- CTNM
- LYEL Biotechnology: Pharmaceutical Preparations
- Sector
- CTNM
- LYEL Health Care
- Exchange
- CTNM Nasdaq
- LYEL Nasdaq
- Market Cap
- CTNM 248.7M
- LYEL 207.7M
- IPO Year
- CTNM 2024
- LYEL 2021
- Fundamental
- Price
- CTNM $12.36
- LYEL $12.82
- Analyst Decision
- CTNM Strong Buy
- LYEL Sell
- Analyst Count
- CTNM 4
- LYEL 2
- Target Price
- CTNM $22.75
- LYEL $15.00
- AVG Volume (30 Days)
- CTNM 278.0K
- LYEL 24.3K
- Earning Date
- CTNM 11-05-2025
- LYEL 11-06-2025
- Dividend Yield
- CTNM N/A
- LYEL N/A
- EPS Growth
- CTNM N/A
- LYEL N/A
- EPS
- CTNM N/A
- LYEL N/A
- Revenue
- CTNM N/A
- LYEL $60,000.00
- Revenue This Year
- CTNM N/A
- LYEL N/A
- Revenue Next Year
- CTNM N/A
- LYEL N/A
- P/E Ratio
- CTNM N/A
- LYEL N/A
- Revenue Growth
- CTNM N/A
- LYEL 11.11
- 52 Week Low
- CTNM $3.35
- LYEL $7.65
- 52 Week High
- CTNM $20.30
- LYEL $32.00
- Technical
- Relative Strength Index (RSI)
- CTNM 73.06
- LYEL 64.71
- Support Level
- CTNM $10.30
- LYEL $12.59
- Resistance Level
- CTNM $13.26
- LYEL $13.50
- Average True Range (ATR)
- CTNM 1.04
- LYEL 0.67
- MACD
- CTNM 0.03
- LYEL 0.18
- Stochastic Oscillator
- CTNM 77.13
- LYEL 76.87
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.